AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension
Completed
- Conditions
- Stable AnginaHypertension
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT01321242
- Locations
- 🇷🇺
Research Site, Ulyanovsk, Russian Federation
Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT01318655
- Locations
- 🇯🇵
Research Site, "Chuo-ku", "Fukuoka", Japan
A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 626
- Registration Number
- NCT01313494
A Bioavailability Study Comparing 3 Different AZD1981 Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD1981, new small-particle tabletDrug: AZD1981, current small-particle tabletDrug: AZD1981, new large-particle table
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT01311635
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects
Phase 1
Completed
- Conditions
- Rheumatoid ArthritisHealthy Subjects
- Interventions
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01311622
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
- First Posted Date
- 2011-03-08
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT01310322
- Locations
- 🇬🇧
Research Unit, London, United Kingdom
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 652
- Registration Number
- NCT01309841
- Locations
- 🇸🇰
Research Site, Presov, Slovakia
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
Phase 1
Completed
- Conditions
- Rheumatoid ArthritisHealthy VolunteersPharmacokineticsPioglitazoneDrug-drug InteractionAmount of Pioglitazone in Blood
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01309854
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week
Completed
- Conditions
- Healthy
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9246
- Registration Number
- NCT01308372
- Locations
- 🇫🇷
Research Site, Yutz, France
BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States
Phase 1
Withdrawn
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01305551
- Locations
- 🇧🇷
Local Institution, Campinas, Sao Paulo, Brazil